Snowball logo
logo
IMA

ImageneBio, Inc.

IMA • NASDAQ
$4.02-$0.03  (0.74%)
Estimate
EPS
-4.43
Beta
1.239
Growth
Net income, YoY
-267.84%
FCF, YoY
-165.14%
Forecast
EPS (FWD)
-4.31
About the company
Ticker
IMA
ISIN
US45175G2075
Country
United States of America
Sector (GICS)
Healthcare
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Frequently asked questions

What sector does ImageneBio, Inc. (IMA) operate in?

ImageneBio, Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.

What is ImageneBio, Inc. (IMA) current stock price?

As of the latest data, ImageneBio, Inc. stock price is $4.02, with a previous close of $4.05. ImageneBio, Inc. lost -$0.03 in the last trading session, representing a -0.74% loss.

What is ImageneBio, Inc. (IMA) current market capitalization?

ImageneBio, Inc. market cap is approximately 45.72 million.

What is ImageneBio, Inc. (IMA) Earnings Per Share (EPS)?

The trailing EPS is -$4.43, and the forward EPS is -$4.31.

What is ImageneBio, Inc. (IMA) EBITDA?

ImageneBio, Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -9.99 million.

Does ImageneBio, Inc. (IMA) pay dividends?

No. ImageneBio, Inc. does not pay a dividend.

When is ImageneBio, Inc. (IMA) next earnings report?

ImageneBio, Inc. is expected to release its next earnings report on September 30, 2026.

What is ImageneBio, Inc. (IMA) beta (volatility) score?

ImageneBio, Inc. has a beta of 1.239, suggesting it is more volatile than the market.